JPWO2020102096A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020102096A5
JPWO2020102096A5 JP2021525223A JP2021525223A JPWO2020102096A5 JP WO2020102096 A5 JPWO2020102096 A5 JP WO2020102096A5 JP 2021525223 A JP2021525223 A JP 2021525223A JP 2021525223 A JP2021525223 A JP 2021525223A JP WO2020102096 A5 JPWO2020102096 A5 JP WO2020102096A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
optionally
hydroxy
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507065A (ja
JP2022507065A5 (https=
JP7730759B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060770 external-priority patent/WO2020102096A1/en
Publication of JP2022507065A publication Critical patent/JP2022507065A/ja
Publication of JPWO2020102096A5 publication Critical patent/JPWO2020102096A5/ja
Publication of JP2022507065A5 publication Critical patent/JP2022507065A5/ja
Priority to JP2024091521A priority Critical patent/JP2024113083A/ja
Application granted granted Critical
Publication of JP7730759B2 publication Critical patent/JP7730759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525223A 2018-11-13 2019-11-11 Nlrp活性に関連する病態を治療するための化合物及び組成物 Active JP7730759B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091521A JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201862760248P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862760209P 2018-11-13 2018-11-13
US62/760,209 2018-11-13
US62/760,244 2018-11-13
US62/760,248 2018-11-13
US201862768811P 2018-11-16 2018-11-16
US62/768,811 2018-11-16
US201862769151P 2018-11-19 2018-11-19
US201862769165P 2018-11-19 2018-11-19
US62/769,165 2018-11-19
US62/769,151 2018-11-19
US201962795919P 2019-01-23 2019-01-23
US62/795,919 2019-01-23
US201962796356P 2019-01-24 2019-01-24
US201962796361P 2019-01-24 2019-01-24
US62/796,361 2019-01-24
US62/796,356 2019-01-24
US201962836577P 2019-04-19 2019-04-19
US201962836585P 2019-04-19 2019-04-19
US201962836575P 2019-04-19 2019-04-19
US62/836,585 2019-04-19
US62/836,577 2019-04-19
US62/836,575 2019-04-19
US201962895595P 2019-09-04 2019-09-04
US62/895,595 2019-09-04
PCT/US2019/060770 WO2020102096A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091521A Division JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Publications (4)

Publication Number Publication Date
JP2022507065A JP2022507065A (ja) 2022-01-18
JPWO2020102096A5 true JPWO2020102096A5 (https=) 2022-11-22
JP2022507065A5 JP2022507065A5 (https=) 2022-11-22
JP7730759B2 JP7730759B2 (ja) 2025-08-28

Family

ID=68841175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525223A Active JP7730759B2 (ja) 2018-11-13 2019-11-11 Nlrp活性に関連する病態を治療するための化合物及び組成物
JP2024091521A Pending JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091521A Pending JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Country Status (31)

Country Link
US (1) US20230031406A1 (https=)
EP (2) EP3880660B1 (https=)
JP (2) JP7730759B2 (https=)
KR (1) KR20210096123A (https=)
CN (2) CN113166065B (https=)
AU (1) AU2019379109B2 (https=)
BR (1) BR112021008969A2 (https=)
CA (1) CA3114918A1 (https=)
CL (1) CL2021001228A1 (https=)
CO (1) CO2021006075A2 (https=)
CR (1) CR20210235A (https=)
DK (1) DK3880660T3 (https=)
EC (2) ECSP21033236A (https=)
ES (1) ES3042546T3 (https=)
FI (1) FI3880660T3 (https=)
HR (1) HRP20251344T1 (https=)
HU (1) HUE073575T2 (https=)
IL (1) IL283042B2 (https=)
JO (1) JOP20210105B1 (https=)
LT (1) LT3880660T (https=)
MA (1) MA54229B1 (https=)
MX (1) MX2021005529A (https=)
MY (1) MY206733A (https=)
PE (1) PE20211698A1 (https=)
PH (1) PH12021500025A1 (https=)
PL (1) PL3880660T3 (https=)
PT (1) PT3880660T (https=)
RS (1) RS67257B1 (https=)
SG (1) SG11202103405TA (https=)
SI (1) SI3880660T1 (https=)
WO (1) WO2020102096A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
JP7392169B2 (ja) * 2019-11-12 2023-12-05 成都百裕制薬股▲ふん▼有限公司 アミド誘導体及びその調製方法並びに医薬における応用
PH12022551767A1 (en) * 2020-01-22 2023-11-29 Hoffmann La Roche Sulfonimidamide compounds as nlrp3 modulators
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116635373A (zh) * 2021-05-10 2023-08-22 成都百裕制药股份有限公司 酰胺衍生物及其应用
CN116917282A (zh) * 2021-05-10 2023-10-20 成都百裕制药股份有限公司 酰胺衍生物及其应用
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116253664A (zh) * 2023-02-01 2023-06-13 山东海科创新研究院有限公司 基于双液相微乳化缩合工艺的accp制备方法
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
US11339136B2 (en) * 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7349981B2 (ja) * 2017-07-24 2023-09-25 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
ES2988798T3 (es) * 2017-07-24 2024-11-21 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
CA3105521A1 (en) * 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Similar Documents

Publication Publication Date Title
JPWO2020102096A5 (https=)
JP2020528889A5 (https=)
JP2020537657A5 (https=)
JP2019515952A5 (https=)
JP2019518071A5 (https=)
EP1838320B1 (en) Cxcr4 antagonists for the treatment of medical disorders
JP7016809B2 (ja) 抗ウイルス剤としての四環式ピリドン化合物
ES2897452T3 (es) 2-Oxo-5H-cromeno[4,3-b]piridinas para su uso en el tratamiento de la hepatitis B
HRP20251344T1 (hr) SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a
JPWO2020086732A5 (https=)
JP7201260B2 (ja) ピリジンアミン-ピリドンおよびピリミジンアミン-ピリドン化合物
RU2008141368A (ru) Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3
US20090124636A1 (en) Chemical compounds
JP6858984B2 (ja) がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物
WO2017216686A1 (en) 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
CA3114240A1 (en) Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP2020525513A (ja) 癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物
US20210346377A1 (en) Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
WO2007049532A1 (ja) アミノジヒドロチアジン誘導体
UA129653C2 (uk) Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування
ES3001444T3 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN111801328A (zh) 自分泌运动因子抑制剂及其用途
CA2575777A1 (en) Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives
JP2021501756A5 (https=)